{"nctId":"NCT00655356","briefTitle":"Safety and Efficacy Study of Isolagen Therapy in the Treatment of Nasolabial Fold Wrinkles","startDateStruct":{"date":"2006-11"},"conditions":["Bilateral Nasolabial Fold Wrinkles"],"count":218,"armGroups":[{"label":"Active","type":"EXPERIMENTAL","interventionNames":["Biological: Autologous Human Fibroblasts (azficel-T)"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: Placebo"]}],"interventions":[{"name":"Autologous Human Fibroblasts (azficel-T)","otherNames":["LAVIV"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subject is at least 18 years of age\n* Level of severity of bilateral nasolabial fold wrinkles meeting severity criteria as per protocol\n* Level of subject dissatisfaction with both nasolabial fold wrinkles as per protocol\n* Ability to comply with the study requirements\n* Negative pregnancy test (Females)\n* Healthy post-auricular skin for biopsy\n\nExclusion Criteria:\n\n* Excessive dermatochalasis of the treatment area\n* Inability to lessen the nasolabial fold wrinkles by physically spreading the area apart\n* Total area to be treated exceeds 20 cm in length\n* Physical attributes which may prevent assessment or treatment as judged by the evaluator\n* Use of an investigational product/procedure within 30 days prior to enrollment or plans for use during the study\n* Previous treatment with the sponsor's product\n* History of active autoimmune disease or organ transplantation\n* Diagnosis of cancer, unless successfully treated or in remission (basal cell carcinoma is excluded)\n* Active or chronic skin disease\n* Known genetic disorders affecting fibroblasts or collagen\n* Active systemic infection\n* Requires chronic antibiotic or steroidal therapy\n* Use of certain commercial products/procedures to the treatment area prior to study enrollment or plans for use during the study\n* Use of systemic agents that increase bleeding or clotting, or disorders equated with these effects\n* Known allergic reactions to agents used in preparation of treatment\n* Excessive exposure to sun without adequate sun protection","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Subject Wrinkle Assessment Responders","description":"A two point improvement on the Subject's live assessment of the wrinkles of the lower part of the face as compared to baseline on the Subject Wrinkle Assessment was considered a responder. The Subject Wrinkle Assessment scale was a five point scale with a score of -2 (Very Dissatisfied) being the worst and a score of +2 (Very Satisfied) being the best.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]}]},{"type":"PRIMARY","title":"Evaluator Wrinkle Severity Assessment Responders","description":"A responder was defined as a two point improvement on the blinded Evaluator's live assessment of each of the bilateral nasolabial fold wrinkles at rest using the 6-point ordinal Lemperle Wrinkle Severity Scale. On the Lemperle scale, a score of 5 (Very Deep Wrinkle) is worst and a score of 0 (No Visible Wrinkle) is best.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Subject Wrinkle Assessment Responders","description":"A two point improvement on the Subject's live assessment of the wrinkles of the lower part of the face as compared to baseline on the Subject Wrinkle Assessment was considered a responder. The Subject Wrinkle Assessment scale was a five point scale with a score of -2 (Very Dissatisfied) being the worst and a score of +2 (Very Satisfied) being the best.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]}]},{"type":"SECONDARY","title":"Evaluator Wrinkle Severity Assessment Responders","description":"A responder was defined as a two point improvement on the blinded Evaluator's live assessment of each of the bilateral nasolabial fold wrinkles at rest using the 6-point ordinal Lemperle Wrinkle Severity Scale. On the Lemperle scale, a score of 5 (Very Deep Wrinkle) is worst and a score of 0 (No Visible Wrinkle) is best.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":98},"commonTop":["Injection site haemorrhage","Injection site erythema","Injection site bruising","Upper respiratory tract infection"]}}}